# Protagonist (PTGX) — News

PTGX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ptgx/news

## Recent headlines

- [Protagonist Therapeutics, Inc.: Leerink partners assumes coverage with outperform rating; target price $190](https://www.ainvest.com/news/protagonist-therapeutics-leerink-partners-assumes-coverage-outperform-rating-target-price-190-2610) — AInvest Wire, Oct 12, 2026
  Leerink Partners has initiated coverage of Protagonist Therapeutics, Inc. with an "outperform" rating and a target price of $190 per share. The decision reflects the firm’s assessment of the company’s therapeutic pipeline and its potential for long-term growth. While specific details of the firm’s…
- [Axis Capital raises PSB bid to EUR 3.20/share vs Bawag](https://www.ainvest.com/news/axis-capital-raises-psb-bid-eur-3-20-share-bawag-2610) — AInvest Wire, Oct 12, 2026
  Axis Capital Holdings Limited (AXS) has increased its bid for Permanent TSB Group Holdings plc (PTSB) to €3.20 per share, valuing the Irish retail bank at approximately €1.62 billion. The revised offer represents a significant step in the ongoing acquisition process, which has been recommended by…
- [Protagonist Therapeutics, Inc.: Citigroup raises target price to $182 from $175](https://www.ainvest.com/news/protagonist-therapeutics-citigroup-raises-target-price-182-175-2609) — AInvest Wire, Sep 1, 2026
  Citigroup has raised its price target for Protagonist Therapeutics, Inc. (NASDAQ: PTGX) to $182 from $175, maintaining its “buy” rating for the stock. This adjustment implies potential upside of approximately 24.6% from the stock’s closing price as of August 29, 2026. The move follows upgrades from…
- [Protagonist Therapeutics, Inc.: H.C. Wainwright raises target price to $170 from $167](https://www.ainvest.com/news/protagonist-therapeutics-wainwright-raises-target-price-170-167-2608) — AInvest Wire, Aug 31, 2026
- [Jefferies lifts its Protagonist Therapeutics price target to $171, up from $169.](https://www.ainvest.com/news/jefferies-lifts-protagonist-therapeutics-price-target-171-169-2608) — AInvest Wire, Aug 31, 2026
  Jefferies has raised its price target for Protagonist Therapeutics (PTGX) to $171, an increase from the previous $169, reflecting a positive outlook on the company’s recent developments and pipeline progress. The adjustment comes amid growing analyst optimism, with 14 analysts currently rating the…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).